Wanbury vs Peers
- Market cap
- ₹679 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹139.95 – ₹262.41
Wanbury ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Wanbury. Its P/E of 22.5 compares with a peer median of 22.5.
Wanbury vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Wanbury | 194.38 | +0.09% | 679 | 22.5 | 2.85 | 14.5% | +18.5% |
| Wanbury | 194.38 | +0.09% | 679 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Wanbury peer comparison — frequently asked questions
Who are Wanbury's competitors?
Wanbury's listed peers in Drug Manufacturers - Specialty & Generic include Wanbury, ranked here by market capitalisation.
How does Wanbury's P/E compare with its peers?
Wanbury trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Wanbury's peers?
By market capitalisation, the largest company in the group is Wanbury at ₹679 crore, against ₹679 crore for Wanbury.
Same Data For Peers
Trade Wanbury With ATS
Track WANBURY live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.